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Food allergy is a major public health problem affecting nearly 10 % of children in most industrialized countries.
Unfortunately, there are no effective therapies for food allergy, relegating patients to simply avoid the offending
foods and treat reactions that occur on accidental exposure. Recently however, studies suggest that food immunotherapy
may provide a promising new approach to food allergy, particularly using the oral form of immunotherapy (OIT).
Enthusiasm for this approach though must be tempered because of the significant allergic reactions that often occur
with OIT that tends to limit its use to patients with less severe disease. On the other hand, recent studies suggest that
concomitant treatment of patients with omalizumab (anti-IgE monoclonal antibody) during the updosing phase of OIT
may greatly reduce the allergic reactions associated with OIT, even in high-risk patients. This combined method may
provide a novel approach to successfully and rapidly treat a large fraction of patients with high-risk food allergy.
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Food allergy is a serious public health problem that affects
4-8 % of children in the US [1, 2]. In Australia, the preva-
lence of peanut allergy alone is 3 % in young children [3];
in the UK it is 2 % of 8-year-old children. In the US, 5 %
of adults are estimated to have food allergy; 1.8 % have
peanut allergy. Moreover, the prevalence of food allergy
appears to have doubled or even quadrupled over the past
15 years in the US, UK and China [4, 5]. Globally, the
number of patients with food allergy is estimated to be
around 220-250 million [6].
In this review we will focus on IgE-mediated food al-
lergy; non-IgE mediated reactions, such as celiac disease,
eosinophilic esophagitis, lactose intolerance or food poi-
soning, will not be discussed. In IgE-mediated food allergy,
reactions begin when allergen binds to IgE bound to the
surface of mast cells or basophils through high-affinity IgE
receptors (FcεR1), triggering the rapid release of media-
tors, generally within minutes, including histamine and
leukotrienes that cause the symptoms of allergy.
Unfortunately for patients with food allergy, there are
no FDA or EMA approved therapies for food allergy, and
the standard of care is allergen avoidance and prompt* Correspondence: umetsu.dale@gene.com
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unless otherwise stated.treatment of allergic reactions when they develop after ac-
cidental ingestion. However, even when attempting strict
avoidance, each patient on average develops a significant
allergic reaction every 1-4 years, due to the fact that the
major food allergens are often hidden in prepared foods,
or may be present due to cross contamination. As a result,
food allergy is currently the most common cause of ana-
phylaxis seen in emergency rooms across the US, with
peanut allergy accounting for 50-60 % of fatal episodes of
anaphylaxis [7]. Furthermore, food allergy can be very
stressful and debilitating for patients and families, because
allergic reactions, including anaphylaxis, occur unpredict-
ably. Maladaptive behaviors and anxiety develop, reducing
quality of life (QoL) in food allergic children to a greater
degree than in children with rheumatologic disease or in
children with insulin-dependent diabetes [8, 9]. Therefore,
food allergy represents an important and urgent unmet
medical need.Novel approaches to the treatment of food allergy
To address this need, food immunotherapy has been in-
vestigated as a treatment and potentially disease modifying
approach. Immunotherapy has been performed subcuta-
neously, sublingually, transdermally and orally [10]. How-
ever, the subcutaneous approach was abandoned many
years ago due to safety concerns [11]; the sublingual andl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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but efficacy is limited by a restricted dose capacity, i.e., the
amount that can be absorbed through the skin or under
the tongue [12]. Oral immunotherapy (OIT) is more ef-
fective than the other routes, in part because much larger
doses can be administered, but safety has been a major
limitation [13]. OIT is performed by administration ini-
tially of low oral doses, after which the dose is increased
as tolerated. Using this method, OIT has been successful
in desensitizing many patients to different foods including
egg, milk, peanut and tree nut [10, 14, 15]. The goal of
therapy in most cases is to reduce or eliminate the severity
of reactions following accidental ingestion, which means
tolerating relatively low oral maintenance doses; but occa-
sionally, the goal of OIT has been to tolerate much greater
maintenance (dietary) doses of the food. However, there is
no consensus regarding the best specific protocol in terms
of dosing schedule and timing of the doses, and currently
OIT is still considered experimental, due to significant
concerns regarding safety and long-term consequences, as
discussed below.
Although OIT can be effective in increasing the
amount of food that can be tolerated by a food allergic
individual, allergic reactions, including anaphylaxis, are fre-
quently observed during the desensitization protocol. For
example, >90 % of patients undergoing oral milk OIT
develop reactions, and 10-20 % of patients require epi-
nephrine at some point during the desensitization process
[16]. A recent meta-analysis of OIT studies suggested that
the frequent serious adverse reactions might outweigh the
benefits of OIT [17, 18]. Moreover, due to frequent allergic
reactions that prevent dose increases, OIT generally takes a
median time of 20-60 weeks to reach maintenance doses,
and the highest oral dose achieved is often below the target
maintenance dose. Importantly, as many as 10-30 % of
food allergic patients are refractory to desensitization, par-
ticularly in patients with higher initial food-specific IgE
levels [19–23]. Given these safety issues, OIT is currently
performed primarily in academic centers, and most experts
strongly believe that it should NOT be recommended for
use in the community [24].
Oral immunotherapy with omalizumab
To address some of the safety issues associated with
OIT, anti-IgE monoclonal antibody (mAb) was proposed
several years ago as an adjunct to facilitate OIT by redu-
cing OIT-induced allergic reactions [25]. Several previ-
ous studies provided the rationale for such an approach.
First, treatment with an anti-IgE mAb called Tnx 901
was shown to increase the threshold dose on peanut
challenge eliciting allergic reactions from a mean of 90
mg to 1,400 mg of peanut protein [26]. Two additional
studies, using another anti-IgE mAb, omalizumab, in-
creased the threshold dose of peanut eliciting allergicreactions on oral peanut challenge [27, 28]. Although
there was no intent in these studies to do desensitization,
these results suggested that anti-IgE mAb might facilitate
oral desensitization.
The first study to use omalizumab with OIT examined
desensitization in patients with high-risk, significant milk
allergy [25]. Eleven subjects were recruited (median age of
8 years), with high milk-specific IgE (median 50 kU/L,
range of 42-342 kU/L) (median total IgE, 349). Patients
were pretreated with omalizumab injections every 2-4
weeks, dosed according to the package insert, except for
the 3 children with serum IgE levels >700 kU/L, where the
dose was 225 to 300 mg (approximately 0.016 mg/kg/IgE
[U/mL]) [25], for nine weeks, at which point desensitization
began, at a starting dose of 0.1 mg milk powder. Eleven
doses were given on the first day, up to a dose of 1,000 mg
of milk powder (cumulative dose 2,000 mg, approximately
1 ounce of milk or 1,000 mg milk protein). 7 of 11 patients
tolerated the highest dose on the first day; one patient
dropped out after the first day of desensitization. The ten
remaining patients received daily doses of milk, with
weekly up-dosing over the following weeks, while continu-
ing omalizumab. Nine of the 10 patients reached the top
dose of 2,000 mg dose, and the 10th patient, who was de-
layed due to allergic reactions, reached a top dose of 1,000
mg of milk by the seventh week of desensitization, at
which point omalizumab was discontinued. Maintenance
daily oral milk continued, and at week 25, a double blind
placebo controlled food challenge (DBPCFC) was per-
formed, with a total of >8,000 mg milk protein or >8
ounces of milk. Nine of the 10 patients tolerated this chal-
lenge, and the 10th patient tolerated 4 ounces of milk. Fol-
lowing the DBPCFC, many of the patients began eating
and enjoying ice cream, pizza and other milk containing
foods.
The peanut OIT study
Based on the success of oral milk desensitization with
omalizumab, omalizumab was tested next with OIT in
high-risk peanut allergic patients. Thirteen patients (median
age 10 years, range (7-15) with a history of high-risk peanut
allergy, including histories of severe reactions, were re-
cruited (median peanut-specific IgE) was 229 kU/L, range
of 21-617 kU/L, the highest median for any oral peanut
desensitization study, as far as we know) (median total IgE,
621 kU/L) [29]. Prior to desensitization, a DBPCFC with
peanut was performed and all patients reacted to peanut
with a median dose of 50 mg peanut protein (<¼ peanut).
The patients were then pretreated with omalizumab (using
European dosing guidelines) for a total of 12 wks, at which
point desensitization started at 0.2 mg of peanut protein,
increasing on the first day to a top dose of 250 mg peanut
protein (10 doses, cumulative dose, 445 mg). On the first
day of the desensitization, all 13 patients reached the top
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or no symptoms. All patients continued on daily oral pea-
nut, and with weekly updosing over the following eight
weeks to a top dose of 2,000 mg of peanut protein (about
8-10 peanuts). 12 of the 13 patients reached the top dose of
2,000 mg of peanut flour in a median time of 8 weeks, at
which point omalizumab was stopped and daily oral main-
tenance of peanut was continued. One patient dropped out
after reaching the 625 mg dose, due to persistent vomiting.
Twelve weeks later, the 12 remaining patients passed a
DBPCFC, tolerating 4,000 mg of peanut protein, the
equivalent of about 16-20 peanuts. Thus, the 12 patients
tolerated 160 to 400 times more peanut than they did
before desensitization.Safety of peanut OIT with omalizumab
Over the course of the 52 week study, including 6
months of observation after discontinuing omalizumab,
reactions were graded using the Bock’s scoring system
[30]. On the first day of peanut desensitization on omali-
zumab, minimal or no allergic symptoms developed as
all 13 subjects tolerated 445 mg of peanut protein. Over
the next eight weeks while on omalizumab, nine patients
(70 % of patients, including the one patient who dropped
out) had 47 mild and 2 moderate reactions. Surprisingly,
3 patients (23 % of the subjects) developed no symptoms
during the whole desensitization process. Thus, while on
omalizumab, no severe reactions occurred. The one sub-
ject who dropped out, began hypersalivation and vomit-
ing after reaching the 625 mg dose. Except for this one
patient, reactions were easily treated with antihistamines,
suggesting that omalizumab can protect against severe
allergic reactions during the desensitization process.
After the omalizumab was discontinued, two subjects
had grade 3 (severe) reactions, all occurring at some
point after tolerating the 2,000 mg dose of peanut pro-
tein or after passing the final DBPCFC. Most of these re-
actions were associated with exercise, infection, stress,
NSAID ingestion or menstrual periods. Reactions during
the maintenance period can thus occur, as has been ob-
served in previous studies of OIT without omalizumab
[23]. These reactions may not be surprising, since the
median peanut-specific IgE at week 52 in our study,
though greatly reduced from the start, was still about
70 kU/L. Nevertheless, all of the reactions responded
rapidly to treatment, and a few days after the reactions
the patients were later able to re-tolerate the 2,000-
4000 mg dose. One patient dropped out after develop-
ing 2 separate allergic reactions to peanut, after suc-
cessfully completing the second DBPCFC. Follow up of
these patients is currently ongoing and expected to last
at least 3-5 years, in order to evaluate if the effect of
this desensitization method is long-lasting and also todetermine if sustained unresponsiveness/tolerance can
be achieved.
Limitations of the peanut OIT study
There are a number of limitations to this pilot phase 1/2
safety peanut study. The sample size was small, there
was no placebo group, and follow-up is limited, although
still on-going. Nevertheless, even without a placebo group,
several points are worth mentioning. First, the patients in
this omalizumab-peanut OIT study had the highest
median peanut-specific IgE level, 229 ku/L, which is im-
portant, since other investigators in studies without omali-
zumab have found that higher food-specific IgE levels are
associated with greater allergic reactions and failure of
patients to be desensitized [19–23]. So in this study, the
high rate of successful desensitization is notable, given the
high level of peanut specific IgE, and the median time of
eight weeks to reach the highest dose of peanut. In con-
trast, in two previous oral peanut desensitization studies
performed without omalizumab, only 10 of 39 patients tol-
erated the first day top desensitization 100 mg peanut pro-
tein dose [31], and in the second study only 6 of 28
patients tolerated the first day 100 mg dose [32]. On the
other hand, in the omalizumab-OIT study, 13 of 13
patients tolerated the 250 mg dose, significantly different
from the previous two non-omalizumab studies with a
P-value <0.0001 (Fisher’s exact test), even though the dose
in the omalizumab study was 2.5 times higher than in the
other two studies. Moreover, with omalizumab treatment,
patients required a median time of 8 weeks to reach the
maintenance dose, whereas in previous studies without
omalizumab, patients required a median time of 20-60
weeks to the reach maintenance dosing. These differences,
particularly given the much higher peanut-specific IgE
levels in the omalizumab study population and the low
failure rate, strongly suggest that omalizumab facilitates
faster oral peanut desensitization with less apparent ad-
verse symptoms than seen historically in other OIT trials.
The idea that omalizumab might facilitate OIT was re-
cently confirmed by a multicenter study performed exam-
ining the role of omalizumab in the treatment of cow’s
milk allergy. In this trial of omalizumab versus placebo
combined with milk OIT, the investigators treated 28
patients with omalizumab and 29 with placebo, and dem-
onstrated that omalizumab significantly reduced dosing
symptoms and OIT-related side effects, including a reduc-
tion in treatments with epinephrine, from 17 doses in the
placebo group to 1 in the omalizumab-treated group (Kim
et al. Abstract L19, AAAAI meeting, San Diego, CA
2014). Omalizumab also reduced the time to achieve
maintenance dosing (from a median of 31 wks to 26 wks).
Additional support for the effectiveness of omalizumab-
facilitated OIT has been provided by two additional publi-
cations. The first of these examined OIT to multiple foods
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food allergies [33]. In this study, 25 patients who had failed
an initial double-blind placebo-controlled food challenge
at protein doses of 100 mg or less were treated with omali-
zumab followed by OIT to up to five foods (median 4
foods) simultaneously. 22 of the subjects safely reached
and maintained the 4,000 mg doses of each food (median
time of 18 wks). A second report described three patients
with high-risk egg allergy, two of whom failed conven-
tional egg OIT after the 8.5 mg dose of egg protein, and
the third who was thought likely to be refractory to egg
OIT because of an ovomucoid-specific IgE of 340 kU/L.
All three were successfully desensitized to egg after receiv-
ing omalizumab [34]. These results together suggest that
omalizumab can facilitate safe OIT, even in patients who
might be refractory to conventional OIT.Summary
In summary, among children with significant milk allergy
or peanut allergy, treatment with omalizumab facilitated
rapid oral desensitization, taking as little as eight weeks
time to achieve daily maintenance with high doses of the
food. Additional follow up of the treated patients how-
ever, is required to assess the long-term benefits of
desensitization. After reaching maintenance dosing and
passing the final DBPCFC, patients occasionally experi-
enced allergic reactions, which were often associated with
exercise, infection, stress, menstruation, and NSAID use.
The duration and frequency of maintenance therapy must
still be worked out. Furthermore, whether sustained un-
responsiveness or immunological tolerance develops is not
yet clear, although it is likely that maintenance dosing for
much longer periods of time will be required to maintain
food allergen unresponsiveness. In any case, additional,
double-blind placebo-controlled studies are required to fur-
ther confirm the initial results. Indeed, a placebo controlled
study of omalizumab in patients with significant peanut
allergy is ongoing, called PRROTECT (Peanut Reactivity
Reduced by Oral Tolerance in an anti-IgE Clinical Trial),
occurring at 4 sites: Boston Children’s Hospital, Stanford
University, Children’s Hospital of Philadelphia, and Lurie
Children’s Hospital in Chicago. If this study and other stud-
ies replicate the initial four studies, and if the beneficial
effects omalizumab-facilitated desensitization persist over
time, then a new treatment paradigm, using omalizumab
with OIT, could improve the clinical approach for patients
with high-risk food allergy.Competing interests
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